**Fortis Healthcare Limited**
Tower-A, Unitech Business Park,
Block-F, South City 1, Sector – 41,
Gurgaon, Haryana – 122 001 (India)
Tel 0124 492 1033
Fax 0124 492 1041
Emergency 105010
Email: secretarial@fortishealthcare.com
Website: www.fortishealthcare.com

**August 06, 2026**

**FHL/SEC/2026-27**

| | |
|---|---|
| **The National Stock Exchange of India Ltd.** | **BSE Limited** |
| **Scrip Symbol: FORTIS** | **Scrip Code: 532843** |

**Sub: Earnings Presentation under Regulation 30 SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015**

Dear Madam/Sir,

Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find enclosed herewith the 'Earning Presentation' for the quarter ended June 30, 2026.

The date and time of occurrence of event is **Thursday, August 06, 2026** at 6:45 Hours (IST).

This is for your information and records.

Thanking you,
Yours Sincerely,

For **Fortis Healthcare Limited**

SATYENDRA CHAUHAN
Digitally signed by SATYENDRA CHAUHAN
Date: 2026.08.06 19:45:18 +05'30'

**Satyendra Chauhan**
**Company Secretary & Compliance Officer**
**M. No. - A14783**

**Encl : As stated above**

# FORTIS HEALTHCARE LIMITED

## EARNINGS PRESENTATION – Q1 FY27

August 06, 2026

# DISCLAIMER

This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company.

Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities of the company for sale in the United States, India or any other jurisdiction.

Securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering in the United States may be made only by means of an offering document that may be obtained from the Company and that will contain detailed information about the Company and its management, as well as financial statements. Any offer or sale of securities in a given jurisdiction is subject to the applicable laws of that jurisdiction.

This presentation contains forward-looking statements based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this presentation, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since that date.

# About Fortis Healthcare



## National Capital Region
2,191
- FMRI, Gurugram
- FEHI, New Delhi
- Shalimar Bagh
- Noida
- Vasant Kunj (O&M)
- Faridabad
- Manesar, Gurugram
- La Femme GK
- Def Col
- C-DOC (O&M)
- Greater Noida
- Adayu

## Himachal Pradesh
81
- Kangra

## Punjab
989
- Mohali
- Ludhiana
- Ludhiana 2
- Amritsar
- Jalandhar

## Rajasthan
275
- Jaipur

## Maharashtra
768
- Mulund
- Vashi
- Kalyan
- SL Raheja (O&M)

## Karnataka
888
**Bengaluru**
- BG Road
- CG Road
- NagarBhavi
- Rajaji Nagar
- Yeshwanthpur
- Kengeri (O&M)
- Richmond Road (O&M)

## West Bengal
385
**Kolkata**
- Anandpur
- FHKI & FMC

## Chhattisgarh
70
- Raigarh (O&M)

## Telangana
271
**Hyderabad**
- Lakdi-Ka-Pul (O&M)
- L.B. Nagar (O&M)

## Tamil Nadu
241
**Chennai**
- Perumbakkam – Sholinganallur (O&M)

Beds

**36 Healthcare Facilities**

**6,150+ Operational Beds^**

**8,100+ Doctors**

**9,500+ Nurses#**

**28,500+ employees**
**(including Agilus)**

4 JCI Accredited

34 NABH Accredited/ Certified

*Note: ^Including ~1,200 O&M beds*
*# Including trainee nurses*

# AGENDA

1. Performance Highlights
    - Earnings and Financial Summary – Q1FY27
2. Performance Review -  Hospital Business
3. Performance Review -  Diagnostics Business
4. Clinical Excellence at Fortis
5. Appendix

# Q1FY27

## PERFORMANCE HIGHLIGHTS

# Q1FY27 SNAPSHOT

| Consolidated Revenue | Consolidated Op EBITDA[1] | Consolidated PBT[2] |
|---|---|---|
| 2,545 Crores | 568 Crores (22.3% Margin) | 354 Crores |
| ↑ 17.5% | ↑ 15.8% | ↑ 4.6% |

| Consolidated PAT[2] | Net Debt / (Cash)[4] | Net Debt to EBITDA[3,4] |
|---|---|---|
| 263 Crores | 2,233 Crores | 1.01x vs 0.92x |
| ↑ 3.6% | | |

1. *Excluding ESOP expenses of ~INR 31 Cr.*
2. *Excluding exceptional items*
3. *Basis Q1 annualized EBITDA*
4. *Net Debt as on 30th June 2026*

# Q1FY27 SNAPSHOT

- Hospital business revenues grew 19% to INR 2,187 Cr versus INR 1,838 Cr in Q1FY26
- Hospital Business Operating EBITDA* stood at INR 471 Cr, up 15.9%; while operating margin was at 21.5% versus 22.1% in Q1FY26. On a like-for-like basis, excluding the impact of the newly acquired / commissioned facilities, the Operating EBITDA margin* in Q1FY27 was ~22%, similar to Q1FY26.
- Q1FY27 hospital business ARPOB was at INR 2.71 Cr per annum vs INR 2.64 Cr in Q1FY26, up 2.6%
- Occupancy for the quarter stood at 68.7% versus 69.0% in Q1FY26
- The company's diagnostics business reported gross revenues of INR 407 Cr versus INR 369 Cr in Q1FY26 growing by 10.2%.
- Operating EBITDA Margin* of the diagnostics business (basis gross revenues) stood at 23.9% versus 23.0% in Q1FY26

**Excluding ESOP expenses of ~INR 31 Cr. Including the ESOP expenses the Operating EBITDA margin stood at 20.1% for Hospital business and 23.8% for Diagnostics business*

# CONSOLIDATED EARNINGS SUMMARY – Q1FY27

*All figures in INR Cr*













^ *Q1FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 31 Cr*

* *Q1FY27 and Q1FY26 PAT excludes exceptional gain of INR 9.5 Cr and INR 12.6 Cr respectively, which pertains primarily to reversal of impairment in an associate Company*

* *Q4FY26 PAT excludes exceptional loss of INR 12.5 Cr which pertains primarily to the impairment of investment in an associate Company*

# CONSOLIDATED EARNINGS SUMMARY

*All figures in INR Cr*







*^ Q1FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 31 Cr*

# Q1FY27

## *HOSPITAL BUSINESS HIGHLIGHTS*

- Occupancy was at 69%, similar to Q1FY26. Occupied beds increased to 3,418 compared to 2,928 in Q1FY26, a growth of 16.7%.
- Revenue from focus specialties comprising Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics and Renal Sciences grew 16.9% and contributed 62% to overall hospital business revenues.
- Revenues from digital channels viz website, mobile application and digital campaigns witnessed a 18.2% YoY growth; contributed 29.2% to overall hospital revenues, compared to 29.5% in Q1FY26.
- International Patient revenues grew 13% to INR 174 Cr in Q1FY27 vs INR 154 Cr in Q1FY26. The business contributed 7.5% to overall hospital business revenues compared to 7.9% in Q1FY26.

**Key Performance Indicators**






# Q1FY27

## *DIAGNOSTIC BUSINESS HIGHLIGHTS*

- Agilus reported gross revenue of INR 407 Cr in Q1FY27 as compared to INR 369 Cr in Q1FY26, a growth of 10%.
- Operating EBITDA stood at INR 97 Cr* in Q1FY27 versus INR 85 Cr in Q1FY26.
- Operating EBITDA Margin (basis gross revenues) stood at 23.9%* versus 23.0% in Q1FY26.




**Q1FY27 Operating EBITDA and margin excludes ESOP expenses of ~INR 0.7 Cr.*

# OPERATING PERFORMANCE

## *HOSPITAL BUSINESS*

| Particulars (INR Cr) | Hospital Business | | |
|---|---|---|---|
| | Q1FY26 | Q4FY26 | Q1FY27 |
| **Operating Revenue** | **1,838** | **2,023** | **2,187** |
| Revenue Growth vs LY | 18.6% | 19.0% | 19.0% |
| **Reported EBITDA** | **415** | **446** | **451** |
| EBITDA growth vs LY | 40.5% | 16.1% | 8.8% |
| **Margin** | **22.6%** | **22.0%** | **20.6%** |
| Less: Other Income^ | 9 | (0) | 11 |
| Add: ESOP Expenses | - | - | 30 |
| **Operating EBITDA** | **406** | **446** | **471** |
| **Margin** | **22.1%** | **22.1%** | **21.5%** |

- *Above financials includes financials of International entities which are part of Fortis group; mainly RHTTM*
- *^Hospital business reported EBITDA for Q1FY27 and Q1FY26 includes other income primarily pertaining to interest on tax refund and interest income*

# OPERATING PERFORMANCE

## *DIAGNOSTIC BUSINESS*

| Particulars (INR Cr) | Diagnostic Business | | |
|---|---|---|---|
| | Q1FY26 | Q4FY26 | Q1FY27 |
| **Operating Revenue** | **369** | **387** | **407** |
| Revenue Growth vs LY | 7.4% | 11.1% | 10.2% |
| **Reported EBITDA** | **91** | **97** | **107** |
| EBITDA growth vs LY | 51.4% | 35.7% | 16.7% |
| **Margin** | **24.7%** | **24.9%** | **26.2%** |
| Less: Other Income incl FX | 7 | 11 | 10 |
| Add: ESOP Expenses | - | - | 1 |
| **Operating EBITDA** | **85** | **85** | **97** |
| **Margin** | **23.0%** | **22.0%** | **23.9%** |
| Adj: One off impact* | - | (9) | - |
| **Operating EBITDA before one off exp** | **85** | **76** | **97** |
| **Margin** | **23.0%** | **20.1%** | **23.9%** |

- ** For Q4FY26, one off impact on revenue pertain primarily to brand fee provision written back and hence the same has been adjusted from revenue and EBITDA translating into margins of 20.1% in Q4FY26.*
- *Diagnostics business revenue is on Gross Basis; Diagnostic business Q1FY27 net revenue (net of inter company elimination) stood at INR 358 Cr versus INR 329 Cr in Q1FY26 and INR 341 Cr in Q4FY26.*

Fortis

# BALANCE SHEET (CONSOLIDATED)

*June 30, 2026*

| Balance Sheet (INR Cr) | Jun 30, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Shareholder's Equity | 9,435 | 10,168 | 10,472 |
| Debt | 2,355 | 2,872 | 2,580 |
| Lease Liabilities (Ind AS 116)* | 274 | 600 | 616 |
| **Total Capital Employed** | **12,064** | **13,640** | **13,667** |
| | | | |
| Net Fixed Assets (including intangibles & CWIP) | 6,928 | 7,944 | 8,021 |
| Goodwill | 4,194 | 4,722 | 4,722 |
| Investments | 184 | 225 | 238 |
| Cash and Cash Equivalents | 486 | 538 | 347 |
| Net Other Assets | 271 | 212 | 340 |
| **Total Assets** | **12,064** | **13,640** | **13,667** |
| | | | |
| **Net Debt / (cash)** | **1,869** | **2,334** | **2,233** |
| **Net Debt to Equity** | **0.20x** | **0.23x** | **0.21x** |

- **Pertains to lease liability on account of adoption of new accounting standard on leases w.e.f. April 1, 2019*
- *Net Debt excludes lease liabilities*
- *Net Debt to EBITDA was at 1.01x vs 0.92x for Q1FY27 and Q1FY26 (basis annualized EBITDA of Q1FY27 and Q1FY26, respectively)*

Fortis

# PERFORMANCE REVIEW

HOSPITALS BUSINESS

# SPECIALTY MIX

## Q1FY26




## Q1FY27




Specialties such as Renal Sciences, Neurosciences and Orthopedics witnessed Y-o-Y revenue growth of 28%, 27% and 23%, respectively

# PAYOR MIX

## Q1FY26




## Q1FY27



# HOSPITAL MARGIN MATRIX

**Q1FY27**

| EBITDA* | No of Facilities | Revenue Contribution | Operational beds | ARPOB (INR Cr) | Occupancy |
|---|---|---|---|---|---|
| **>20%** | 14 | 70.3% | 3,212 | 2.71 | 74% |
| **15% - 20%** | 4 | 18.0% | 809 | 3.19 | 66% |
| **10% - 15%** | 2 | 4.1% | 331 | 2.08 | 54% |
| **<10%** | 4^ | 6.4% | 588 | 1.93 | 54% |

** Operating EBITDA margin excludes ESOP expenses*

**FY26**

| EBITDA | No of Facilities | Revenue Contribution | Operational beds | ARPOB (INR Cr) | Occupancy |
|---|---|---|---|---|---|
| **>20%** | 13 | 76.2% | 3,238 | 2.66 | 72% |
| **15% - 20%** | 4 | 11.6% | 559 | 2.52 | 69% |
| **10% - 15%** | 1 | 2.2% | 119 | 2.21 | 67% |
| **<10%** | 6^ | 8.8% | 875 | 1.62 | 52% |

*^ Note: <10% EBITDA Margin facilities include Yeshwanthpur (acquired in Jan'26), Manesar (commissioned in Sep'24) and Greater Noida (converted to lease arrangement from Sep'25)*

# PERFORMANCE REVIEW

## DIAGNOSTICS BUSINESS

# DIAGNOSTICS BUSINESS

- During Q1FY27, Agilus conducted 10.46 Mn tests, versus 10.13 Mn in Q1FY26.
- Agilus added 200+ Customer touchpoints* to its network in Q1FY27.
- Agilus' B2C: B2B revenue mix stood at 53:47 in the quarter vs 51:49 in Q1FY26.
- Operating EBITDA stood at INR 97 Cr ^ in Q1FY27 versus INR 85 Cr in Q1FY26.
- Operating EBITDA Margin (basis gross revenues) stood at 23.9%^ versus 23.0% in Q1FY26.




^In Q1FY27 Operating EBITDA and margin excludes ESOP expenses of INR 0.7 Cr
*Note: Gross additions

# QUARTERLY REVENUE MIX

### Geographic mix

### Product Mix

### Segment Mix

Q1FY27










Q1FY26







# QUARTERLY KEY PERFORMANCE METRICS






# CLINICAL EXCELLENCE AT FORTIS

KEY HIGHLIGHTS

# CLINICAL EXCELLENCE & MEDICAL PROGRAMS

## Clinical Excellence

- **Fortis Escorts, Okhla Road, New Delhi,** conducted a 10-hour surgery to remove a rare cancerous tumour (abdominal sarcoma) weighing 14.5 kg from the stomach of a 55-year-old female patient. This is one of the largest and most complex abdominal tumour reported in the country.

- **Fortis Hospital, Vasant Kunj,** successfully treated a 51-year-old man suffering from Walled-Off Pancreatic Necrosis (WOPN), a rare and potentially life-threatening complication of acute pancreatitis, through an advanced robotic pancreatic necrosectomy.

## Augmenting Medical Programs

- **Fortis Escorts, Okhla Road, New Delhi and Fortis Escorts Hospital, Faridabad,** inaugurated advanced Da Vinci Xi Robotic Surgical Systems.

- **Fortis Hospital, Gurugram**, launched India's First Centre of Excellence for Myeloma & Lymphoma under the Institute of Blood Disorders.

- **Fortis Hospital, Noida**, launched the Institute of Neurosciences, aimed at offering comprehensive and integrated care for brain and spine disorders.

**Above data pertains to Q1FY27*

# APPENDIX

# GROUP CONSOLIDATED P&L – Q1FY27

| Particulars ( INR Cr) | Q1FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| **Revenue from operations** | **2,166.7** | **2,364.7** | **2,545.0** |
| Other income | 15.4 | 4.4 | 14.5 |
| **Total income** | **2,182.1** | **2,369.1** | **2,559.5** |
| Expenses | 1,676.0 | 1,832.3 | 2,007.9 |
| **EBITDA*** | **506.1** | **536.7** | **551.6** |
| **Margin** | **23.4%** | **22.7%** | **21.7%** |
| Finance costs | 69.6 | 84.3 | 80.4 |
| Depreciation and amortisation expense | 101.5 | 122.0 | 121.9 |
| **PBT** | **335.0** | **330.5** | **349.3** |
| Share of profit / (loss) of associates and joint ventures (net) | 2.9 | 6.2 | 4.4 |
| **Net profit / (loss) before exceptional items and tax** | **337.9** | **336.7** | **353.6** |
| Exceptional gain/(loss)** | 12.6 | (12.5) | 9.5 |
| **Profit / (loss) before tax from continuing operations** | **350.6** | **324.2** | **363.2** |
| Tax expense / (credit) | 83.8 | 53.0 | 90.4 |
| **Net profit / (loss) for the period from continuing operations** | **266.8** | **271.2** | **272.8** |
| **Profit / (loss) from continuing operations attributable to Owners of the company** | **260.3** | **265.8** | **266.4** |

** EBITDA includes other income, forex, ESOP expenses and exceptional/non-recurring expenses*

***  Q1FY27 and Q1FY26 exceptional gain pertains primarily to reversal of impairment in an associate Company*

*** Q4FY26 exceptional loss  pertains primarily to the impairment of investment in an associate Company*

Fortis

# THANK YOU